

## Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study.

[Wagenlehner FM](#)<sup>1</sup>, [van Oostrum E](#), [Tenke P](#), [Tandogdu Z](#), [Çek M](#), [Grabe M](#), [Wullt B](#), [Pickard R](#), [Naber KG](#), [Pilat A](#), [Weidner W](#), [Bjerklund-Johansen TE](#); [GPIU investigators](#).

### Collaborators (87)

[Moneim KA](#), [Hussein AA](#), [Fu Y](#), [Aghelnezhad R](#), [Hamasuna R](#), [Wada K](#), [Wu FM](#), [Na YG](#), [Baik S](#), [Sukju K](#), [Lee SJ](#), [Han CH](#), [Ahmad M](#), [Elsayed M](#), [Bazardzanovic M](#), [Bajramovic S](#), [Mecl J](#), [Prosvic P](#), [Stanek R](#), [Kingo PS](#), [Andreassen KH](#), [Nelovkov A](#), [Bach C](#), [Botto H](#), [Wicht J](#), [Fiebich J](#), [Morgenstern SC](#), [Miller S](#), [Rusz A](#), [Ludwi M](#), [Varga Z](#), [Löhmann C](#), [Schwindl B](#), [Voudoukis T](#), [Tenke P](#), [Paczelt A](#), [Árpád S](#), [Rosecker Á](#), [Gécs S](#), [Guarriello A](#), [Lodde M](#), [Trinchieri A](#), [Sandri SD](#), [Costantini E](#), [Sacco E](#), [Cai T](#), [Ristovski SP](#), [Glavinov MS](#), [Adamczyk P](#), [Guerra BA](#), [Pereira J](#), [Gameiro CD](#), [Correia TP](#), [Negru DG](#), [Manea CN](#), [Sinyakova LA](#), [Zaytsev AV](#), [Khammatov R](#), [Tamara PS](#), [Maliavin A](#), [Beck J](#), [Kocis L](#), [Mugica MA](#), [Cubillana PL](#), [Montesino-Semper M](#), [Campa J](#), [Hernández DH](#), [Cuesta-Alcala JA](#), [Grabe M](#), [Wirth GJ](#), [Klein J](#), [Arda E](#), [Sofikerim M](#), [Mutlu N](#), [Kilinc M](#), [Oksay T](#), [Citgez S](#), [Ulusoy S](#), [Unluer SE](#), [Donat R](#), [Derbyshire L](#), [Saxby MF](#), [Stanislavovich KV](#), [Staneloni MI](#), [Altclas JD](#), [Militello JI](#), [Heldwein F](#).

### Author information

#### Abstract

**BACKGROUND:** Infection is a serious adverse effect of prostate biopsy (P-Bx), and recent reports suggest an increasing incidence.

**OBJECTIVE:** The aim of this multinational multicentre study was to evaluate prospectively the incidence of infective complications after P-Bx and identify risk factors.

**DESIGN, SETTING, AND PARTICIPANTS:** The study was performed as an adjunct to the Global Prevalence Study of Infections in Urology (GPIU) during 2010 and 2011. Men undergoing P-Bx in participating centres during the 2-wk period commencing on the GPIU study census day were eligible.

**OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:** Baseline data were collected and men were questioned regarding infective complications at 2 wk following their biopsy. The Fisher exact test, Student t test, Mann-Whitney U test, and multivariate regression analysis were used for data analysis.

**RESULTS AND LIMITATIONS:** A total of 702 men from 84 GPIU participating centres worldwide were included. Antibiotic prophylaxis was administered prior to biopsy in 98.2% of men predominantly using a fluoroquinolone (92.5%). Outcome data were available for 521 men (74%). Symptomatic urinary tract infection (UTI) was seen in 27 men (5.2%), which was febrile in 18 (3.5%) and required hospitalisation in 16 (3.1%). Multivariate analysis did not identify any patient

subgroups at a significantly higher risk of infection after P-Bx. Causative organisms were isolated in 10 cases (37%) with 6 resistant to fluoroquinolones. The small sample size per participating site and in compared with other studies may have limited the conclusions from our study.

**CONCLUSIONS:** Infective complications after transrectal P-Bx are important because of the associated patient morbidity. Despite antibiotic prophylaxis, 5% of men will experience an infective complication, but none of the possible factors we examined appeared to increase this risk. Our study confirms a high incidence of fluoroquinolone resistance in causative bacteria.

Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

### Comment in

Prostate biopsies should be performed according to a standard of care. [Eur Urol. 2013]

PMID: 22704727 [PubMed - indexed for MEDLINE]

---

**Publication Types, MeSH Terms, Substances**

---

**LinkOut - more resources**

---

**PubMed Commons**

[PubMed Commons home](#)

0 comments

[How to join PubMed Commons](#)